Literature DB >> 12636301

Prophylactic feeding of Lactobacillus acidophilus NCFM to mice attenuates overt colonic hyperplasia.

Jeffrey J Varcoe1, Gary Krejcarek, Frank Busta, Linda Brady.   

Abstract

The objective of this project was to determine if the probiotic Lactobacillus acidophilus NCFM would protect mice from developing transmissible murine colonic hyperplasia (TMCH) caused by Citrobacter rodentium. Our hypothesis was that the oral administration of L. acidophilus NCFM to mice would mitigate colonic hyperplasia and modulate the host immune response. A concurrent administration (CA) study was performed by feeding mice phosphate-buffered saline (PBS), C. rodentium only, L. acidophilus NCFM only, or C. rodentium and NCFM concurrently on the same day. The mice in the CA study were not protected by the probiotic, since their mean colon sample weights (0.109 g) were significantly higher than those of the PBS controls (0.0774 g), and the hematoxylin and eosin-stained samples showed histological changes typically associated with TMCH. A prophylactic feeding (PF) study was performed by orally feeding mice PBS or NCFM once daily for 20 consecutive days; in addition, on day 7, mice were challenged with either PBS or C. rodentium. Mice in the PF study were protected when they consumed the probiotic prior to the pathogen challenge, since their mean colon sample weights (0.0812 g) were not significantly higher than those of the controls (0.0753 g). The hematoxylin and eosin-stained samples appeared similar to the control samples, and the intestinal interleukin (IL)-15 and gamma interferon (IFN-gamma) mRNA levels were reduced. L. acidophilus NCFM did attenuate overt colonic hyperplasia when fed to mice prior to challenge with C. rodentium. The mouse model used in this study enabled us to investigate the efficacy of the L. acidophilus NCFM in preventing gastrointestinal disease and is a valid model for future probiotic research.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636301     DOI: 10.4315/0362-028x-66.3.457

Source DB:  PubMed          Journal:  J Food Prot        ISSN: 0362-028X            Impact factor:   2.077


  7 in total

1.  Genetic analysis of two bile salt hydrolase activities in Lactobacillus acidophilus NCFM.

Authors:  Olivia McAuliffe; Raul J Cano; Todd R Klaenhammer
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

2.  Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.

Authors:  Benoit Foligne; Sophie Nutten; Corinne Grangette; Véronique Dennin; Denise Goudercourt; Sabine Poiret; Joelle Dewulf; Dominique Brassart; Annick Mercenier; Bruno Pot
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

3.  Effect of probiotics Lactobacillus acidophilus on Citrobacter rodentium colitis: the role of dendritic cells.

Authors:  Chien-Chang Chen; Cheng-Hsun Chiu; Tzou-Yien Lin; Hai Ning Shi; W Allan Walker
Journal:  Pediatr Res       Date:  2009-02       Impact factor: 3.756

4.  Global analysis of carbohydrate utilization by Lactobacillus acidophilus using cDNA microarrays.

Authors:  Rodolphe Barrangou; M Andrea Azcarate-Peril; Tri Duong; Shannon B Conners; Robert M Kelly; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

5.  Mast cells limit systemic bacterial dissemination but not colitis in response to Citrobacter rodentium.

Authors:  Olivia L Wei; Ashley Hilliard; Daniel Kalman; Melanie Sherman
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

6.  Lactobacillus delbrueckii subsp. lactis (strain CIDCA 133) stimulates murine macrophages infected with Citrobacter rodentium.

Authors:  Ayelén A Hugo; Ivanna S Rolny; David Romanin; Pablo F Pérez
Journal:  World J Microbiol Biotechnol       Date:  2017-02-07       Impact factor: 3.312

7.  Host and microbiota factors that control Klebsiella pneumoniae mucosal colonization in mice.

Authors:  Helen Y Lau; Gary B Huffnagle; Thomas A Moore
Journal:  Microbes Infect       Date:  2008-08-13       Impact factor: 2.700

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.